SF3B4的泛癌致癌特性及治疗潜力
Pan-cancer oncogenic properties and therapeutic potential of SF3B4.
作者信息
Shi Yanmei, Pan Qimei, Chen Wenli, Xie Limin, Tang Shiru, Yang Zhizhi, Zhang Man, Yin Dong, Lin Lehang, Liao Jian-You
机构信息
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, PR China.
Center for Bioresources and Drug Discovery and School of Biosciences and Biopharmaceutics, Guangdong Province Key Laboratory for Biotechnology Drug Candidates, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China.
出版信息
Cancer Gene Ther. 2025 May 20. doi: 10.1038/s41417-025-00910-y.
Splicing factor 3B (SF3B) subunit 4 (SF3B4), an SF3B complex component essential for spliceosome assembly and accurate splicing, plays a major role in cancer development. However, the precise mechanism through which SF3B4 contributes to tumor growth remains unclear. Here, we demonstrate that SF3B4 is strongly expressed in patients with various cancer types and correlated with their survival. By using hepatocellular carcinoma (HCC) as a model, we reveal that SF3B4's interactions with and regulatory influence on the checkpoint protein BUB1 are essential for appropriate cancer cell mitosis and proliferation. Our results thus demonstrate the roles of SF3B4 as both a cell-cycle regulator and an oncogenic factor in HCC, highlighting its potential as a pan-cancer therapeutic target and diagnostic biomarker.
剪接因子3B（SF3B）亚基4（SF3B4）是剪接体组装和精确剪接所必需的SF3B复合物的一个组成部分，在癌症发展中起主要作用。然而，SF3B4促进肿瘤生长的确切机制仍不清楚。在此，我们证明SF3B4在多种癌症类型的患者中高表达，并与其生存率相关。以肝细胞癌（HCC）为模型，我们揭示了SF3B4与检查点蛋白BUB1的相互作用及其对BUB1的调节影响对于适当的癌细胞有丝分裂和增殖至关重要。因此，我们的结果证明了SF3B4在HCC中作为细胞周期调节因子和致癌因子的作用，突出了其作为泛癌治疗靶点和诊断生物标志物的潜力。
Zotero 插件